Table 2: Adverse Events graded based on CTCAE 4.0.
|
Apatinib (N=26) |
|||
|
Adverse Events |
Grade 1/2, n (%) |
Grade 3, n (%) |
Grade 4, n (%) |
|
Hematologic |
|||
|
Leukopenia |
8(30.8) |
1(3.8) |
1(3.8) |
|
Neutropenia |
6(23.1) |
1(3.8) |
− |
|
Thrombocytopenia |
4(15.4) |
− |
− |
|
Anemia |
10(38.5) |
2(7.7) |
− |
|
Non-hematologic |
|||
|
Proteinuria |
3(11.5) |
− |
− |
|
Hypertension |
6(23.1) |
1(3.8) |
− |
|
Bleeding |
2(7.7) |
− |
− |
|
Esophageal fistula |
− |
1(3.8) |
− |
|
Fatigue |
6(23.1) |
1(3.8) |
− |
|
Appetite loss |
9(34.6) |
− |
− |
|
Nausea |
7(26.9) |
− |
− |
|
Vomiting |
5(19.2) |
− |
− |
|
Abdominal pain |
4(15.4) |
− |
− |
|
Diarrhea |
6(23.1) |
− |
− |
|
Hand-foot skin reaction |
3(11.5) |
− |
− |
|
Hypoproteinemia |
3(11.5) |
− |
|
|
Hypocalcemia |
2(7.7) |
1(3.8) |
− |
|
Liver function |
|||
|
Hyperbilirubinemia |
4(15.4) |
− |
− |
|
Elavated trasaminase |
5(19.2) |
− |
− |
|
Renal disorder |
|||
|
Creatinine clearance decrease |
2(7.7) |
− |
− |
|
Hypothyroidism |
4(15.4) |
1(3.8) |
− |
|
Others |
|||
|
Heart failure |
− |
1(3.8) |
− |
CTCAE: Cancer Institute’s Common Terminology Criteria for Adverse Events.